MARCHF4

Across TCGA pan-cancer cohorts, MARCHF4 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated MARCHF4 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MARCHF4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MARCHF4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, HNSC, and COAD are the cancer types where MARCHF4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.068	0.605	<.001	42	view →
HNSC	OS	Median	III,IV	0.198	0.745	.003	27	view →
COAD	OS	Median	IV	0.045	0.659	<.001	21	view →
ESCA	OS	Median	II,III,IV	0.325	0.713	.001	18	view →
SKCM	OS	Median	All	0.176	0.789	<.001	15	view →
KIRP	OS	Median	All	0.135	0.703	.002	12	view →
UCEC	DFS	Median	All	1.000	0.622	.015	12	view →
STAD	OS	Median	III,IV	0.143	0.502	.022	9	view →
LIHC	DFS	Median	All	0.099	0.555	.002	9	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
LUAD	OS	Median	All	0.105	0.377	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MARCHF4–BLCA (OS)

Open the BLCA breakdown →